Report of Foreign Issuer (6-k)
June 26 2019 - 12:50PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For the
month of June, 2019
Commission
File Number 001-38522
Realm Therapeutics plc
(Translation
of registrant’s name into English)
267 Great Valley Parkway
Malvern, PA 19355
(Address
of principal executive office)
Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT
ON FORM 6-K
On 26 June 2019, Realm Therapeutics plc
(“
Realm
” or the “
Company
”) (NASDAQ: RLM)
announces
that, further to the announcement of 24 June 2019 that the resolutions proposed at the Court Meeting and the General Meeting in
relation to the Scheme were all approved, the Court Hearing to sanction the Scheme has been rescheduled to 8 July 2019, later than
expected, due to a shareholder opposing the Scheme. Realm expects that the Scheme will become effective (and the Acquisition will
complete) on 10 July 2019, if the Court sanctions the Scheme. The Company will announce an updated timetable of principal events
in due course.
Unless
otherwise defined herein, capitalised terms and expressions used in this announcement shall have the meanings given to them in
the Scheme Document.
The Exhibit to this Report on Form 6-K
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any
filing of the Company under the Securities Act of 1933 or the Exchange Act.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
Realm Therapeutics plc
|
|
|
|
June 26, 2019
|
By:
|
/s/ Marella Thorell
|
|
|
|
Marella Thorell
|
|
|
Chief Financial Officer and Chief Operating Officer
|
Realm Therapeutics (NASDAQ:RLM)
Historical Stock Chart
From May 2024 to Jun 2024
Realm Therapeutics (NASDAQ:RLM)
Historical Stock Chart
From Jun 2023 to Jun 2024